To order this 250+ page report, which features 140+ figures
and 170+ tables, please visit this
Key Inclusions
§ A
detailed assessment of the current market landscape of endocannabinoid system
targeted therapeutics, providing information on phase of development (clinical,
preclinical, and discovery stage) of lead candidates, target therapeutic area
(s), route of administration (oral, topical, sublingual, oromucosal, inhalation
and others), dosing frequency (once daily, twice daily, thrice daily and
others) and target receptor (CB1, CB2, TRPV-1 and others). Additionally, the
chapter includes information on drug developer(s), including information on
year of establishment, company size, and location of headquarters.
§ Elaborate
profiles of prominent endocannabinoid system targeted therapeutics developers
that are engaged in the development of at least four development programs. Each
profile features a brief overview of the company, its financial information (if
available), product portfolio and an informed future outlook.
§ An
in-depth analysis of nearly 600 grants that have been awarded to research
institutes engaged in endocannabinoid system targeted projects, in the period
between 2016 and 2020 (till January), including analysis based on
important parameters, such as year of grant award, amount awarded,
administration institute centre, funding institute centre, support period, type
of grant application, purpose of grant award, grant mechanism, responsible
study section, prominent program officers, and type of recipient organizations.
§ An
analysis of the partnerships that have been established in the recent past,
covering acquisitions, licensing agreements, product development and
commercialization agreements, research agreements, clinical trial agreements,
joint venture agreements and other relevant types of deals.
§ A
detailed analysis of the various mergers and acquisitions that have taken place
in this domain, highlighting the trend in the number of companies acquired
between 2016-2020, based on parameters, such as year of acquisition, type of
acquisition, geographical location of the acquirer and the acquired company,
key value drivers, and financial details of the deal (if available). In
addition, the chapter evaluates the deal multiples of acquisitions specifically
focused on endocannabinoid system targeted therapeutics, analysing them based
on a number of parameters, namely annual revenues, number of employees and experience
of the acquired company. Moreover, it presents a schematic world map
representation of the geographical distribution of this activity, highlighting
inter- and intracontinental deals.
§ An
insightful chessboard analysis highlighting the most popular drug development
strategies / paths adopted by various drug developers (with clinical
candidates) in order to progress their lead drug candidates.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
§
§
§
§
§
§
§
§
§
§
§
§
To request sample pages, please visit this - https://www.rootsanalysis.com/reports/316/request-sample.html
Key
Questions Answered
§
§
§
§
§
§
§
You may also be interested in the
following titles:
1. Neoantigen Targeted
Therapies
2.
3.
4. Continuous
Manufacturing
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
